Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11225115 | 0.89 | SMN1; SMN2 (0.55) | LMNAHSD17B10L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL28958140 | 0.84 | HPGD (0.54) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL2823791 | 0.84 | SLC6A2 (0.53) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL4935875 | 0.84 | SLC6A2 (0.53) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL12600893 | 0.83 | HDAC8 (0.51) | TDP1RAB9AMAPK1NPC1SLC6A3 | |
| SCHEMBL3033043 | 0.82 | SLC6A2 (0.47) | LMNACES1CES2RAB9AMAPT | |
| SCHEMBL3110619 | 0.82 | GSK3B (0.48) | ADRA2BLMNATDP1ALDH1A1CES1 | |
| SCHEMBL648332 | 0.81 | CES2 (0.47) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL10858699 | 0.81 | PGR (0.53) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL7878318 | 0.80 | HTT (0.51) | LMNAL3MBTL1ALDH1A1CES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1150961-B1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI SYNTHELABO (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2002-12-12 | — | — | US | claimed |
| CN-1346349-A | Pyrazoelcarboxylic acid derivatives, their preparation, pharmaceutical compositions containing | SANOFI SYNTHELABO (FR) | 2002-04-24 | — | — | CN | claimed |
| EP-1150961-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| WO-2000046209-A1 | PYRAZOLECARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| JP-63174971-A | — | — | None | — | — | JP | disclosed |
| US-11919908-B2 | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| WO-2022140231-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| EP-0151094-A2 | Pharmacologically active imidazopyridine compounds | RBS PHARMA (ROGER BELLON SCHOUM) S.p.A. (IT) | 1985-08-07 | — | — | EP | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0019796-A1 | Propionic acid esters, preparation of these compounds, herbicides containing these compounds as active substances, and the use of such compounds and agents for combating weeds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-12-10 | — | — | EP | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| US-3976695-A | Halogen substituted α-(aminoalkyl)-3,4-dihydroxybenzyl alcohols | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3954871-A | ANTIARRHYTHMIA, VASODILATOR, HYPOTENSIVE | CONTINENTAL PHARMA (BE) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919908-B2 | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors | JAK2, JAK3, JAK1 | PGR 1293/4885ADRA2A 4316/4885ADRA2B 4216/4885 |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, VHL | PGR 2322/4885ADRA2A 4321/4885ADRA2B 4274/4885 |
| US-20040039024-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | PGR 2074/4885ADRA2A 152/4885ADRA2B 126/4885 |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | DOT1L, KDM1B, KDM1A | PGR 2441/4885ADRA2A 967/4885ADRA2B 1052/4885 |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | KDM1B, KDM1A, DOT1L | PGR 2355/4885ADRA2A 856/4885ADRA2B 817/4885 |
| US-20020188007-A1 | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | CNR1, CNR2, P2RY1 | PGR 2074/4885ADRA2A 152/4885ADRA2B 126/4885 |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | PGR 2441/4885ADRA2A 967/4885ADRA2B 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.